What's new in preventing and treating osteoporosis?

Bone mineral density reaches its peak between the ages of 30 and 35 in women. Thereafter, without intervention, bone loss continues gradually, with a significant acceleration in the first 5 to 6 years after menopause. For decades, estrogen replacement has been the mainstay in preventing bone loss an...

Full description

Saved in:
Bibliographic Details
Published in:Postgraduate medicine 1998-10, Vol.104 (4), p.89-97
Main Author: Andrews, William C.
Format: Article
Language:English
Subjects:
Alendronate - pharmacology
Alendronate - therapeutic use
Bone Density - drug effects
Estrogen Replacement Therapy
Estrogens - adverse effects
Estrogens - pharmacology
Estrogens - therapeutic use
Female
Humans
Middle Aged
Osteoporosis, Postmenopausal - drug therapy
Osteoporosis, Postmenopausal - prevention & control
Progestins - pharmacology
Progestins - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bone mineral density reaches its peak between the ages of 30 and 35 in women. Thereafter, without intervention, bone loss continues gradually, with a significant acceleration in the first 5 to 6 years after menopause. For decades, estrogen replacement has been the mainstay in preventing bone loss and treating osteoporosis after menopause, and it remains first-line therapy. However, not all women are able or willing to use estrogen, so effective alternatives have been developed. In this article, Dr Williams summarizes findings of recent research concerning optimal use of estrogen as well as alendronate, etidronate, raloxifene, calcitonin-salmon, and other measures to manage osteoporosis.
ISSN:0032-5481
1941-9260
DOI:10.3810/pgm.1998.10.445